Renaissance Capital logo

INSY News

US IPO Recap: Activity remains robust with five pricings, five setting terms and four new filers

Following last week's market break, US IPO activity resumed where it left off last week with five pricings, including ING U.S. (VOYA), which raised $1.3 billion. However, overall performance was subpar, with four of five of the deals achieving a total return...read more

Insys Therapeutics prices IPO at $8, at the low end of the revised range

Insys Therapeutics, which markets an opioid and synthetic marijuana drug for cancer pain and CINV, raised $32 million by offering 4 million shares at $8, at low end of the range of $8 to $10. The company had previously filed to offer 4 million shares at a range...read more

Insys Therapeutics decreases range, now plans to raise $36 million

Insys Therapeutics, which markets opioid and synthetic marijuana drugs for cancer pain and CINV, lowered the proposed deal size for its upcoming IPO on Thursday. The Phoenix, AZ-based company now plans to raise $36 million by offering 4 million shares at a price...read more

6 US IPOs planned for the week of Apr 29

The following IPOs are expected to price this week: BioAmber (BIOA), which converts renewable feedstocks into bio-succinic acid and other chemicals, plans to raise $128...read more